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Charcot-Marie-Tooth disease type 2A (CMT2A) is an axonal neuropathy caused by mutations in the mitofusin 2 (MFN2)
gene. MFN2 mutations result in profound mitochondrial abnormalities, but the mechanism underlying the axonal pathology
is unknown. Sterile α and Toll/IL-1 receptor motif–containing 1 (SARM1), the central executioner of axon degeneration, can
induce neuropathy and is activated by dysfunctional mitochondria. We tested the role of SARM1 in a rat model carrying a
dominant CMT2A mutation (Mfn2H361Y) that exhibits progressive dying-back axonal degeneration, neuromuscular junction (NMJ)
abnormalities, muscle atrophy, and mitochondrial abnormalities — all hallmarks of the human disease. We generated Sarm1KO (Sarm1–/–) and Mfn2H361Y Sarm1 double-mutant rats and found that deletion of Sarm1 rescued axonal, synaptic, muscle, and
functional phenotypes, demonstrating that SARM1 was responsible for much of the neuropathology in this model. Despite the
presence of mutant MFN2 protein in these double-mutant rats, loss of SARM1 also dramatically suppressed many mitochondrial
defects, including the number, size, and cristae density defects of synaptic mitochondria. This surprising finding indicates
that dysfunctional mitochondria activated SARM1 and that activated SARM1 fed back on mitochondria to exacerbate the
mitochondrial pathology. As such, this work identifies SARM1 inhibition as a therapeutic candidate for the treatment of CMT2A
and other neurodegenerative diseases with prominent mitochondrial pathology.

Introduction

Charcot-Marie-Tooth disease type 2A (CMT2A) is a common
hereditary motor and sensory neuropathy of the peripheral nervous system characterized by progressive, length-dependent axonal degeneration without myelin involvement that predominantly affects the distal limbs. CMT2A tends to have an earlier onset
and faster progression than do most CMTs, leaving many patients
nonambulatory as children (1, 2). As with all CMTs, there are no disease-modifying treatments. CMT2A is caused by mutations in the
mitofusin 2 (MFN2) gene. MFN2 is a nucleus-encoded dynaminlike GTPase residing in the outer membrane of mitochondria that
plays a critical role in mitochondrial fusion, but also promotes
mitochondrial mobility, mitophagy, and interorganelle calcium
signaling (3). In patients with CMT2A, neuronal mitochondria have
morphological and functional abnormalities (2, 4, 5), but how these
mitochondrial defects result in dying-back axon loss is unknown.
Sterile α and Toll/IL-1 receptor motif–containing 1 (SARM1)
is the central executioner of the programmed axon destruction
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pathway (6, 7) and so is a candidate to mediate axon loss in
CMT2A. SARM1 is an enzyme that, when activated, cleaves the
essential metabolic cofactor NAD+ (8), inducing a stereotyped
local metabolic collapse with loss of ATP, defects in mitochondrial depolarization and motility defects, followed by calcium influx
and ultimately axon fragmentation (9). Loss of SARM1 blocks
axon degeneration in mouse models of axotomy (10, 11), traumatic
brain injury (12), and glaucoma (13). Notably, loss of SARM1 also
preserves axons in multiple models of chemotherapeutic and metabolic peripheral neuropathy (14–18). Nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) is an NAD+ synthesizing
enzyme whose loss results in an increase in nicotinamide mononucleotide (NMN) (19) and hence an increase in the NMN/NAD+
ratio, enabling NMN to displace NAD+ from an allosteric binding
site in the autoinhibitory domain of SARM1, triggering SARM1
activation (20). In a mouse model of a human motor neuropathy
caused by loss of NMNAT2, SARM1 mediates a slowly progressive
motor-predominant neuropathy with axon loss and muscle atrophy (21), both hallmarks of CMT2A. Finally, genetic variants of
SARM1 that encode constitutively active enzymes are enriched in
patients with amyotrophic lateral sclerosis (ALS) and other motor
neuropathies (22, 23). In addition to the strong evidence that
SARM1 induces axon loss in neuropathies, there is also a wealth
of data demonstrating that mitochondrial dysfunction activates
SARM1 (24–27). Thus, we hypothesized that SARM1 may be activated in CMT2A neurons and induce axon loss. If SARM1 promotes
1
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neuropathology in CMT2A, this would open new possibilities for
treatment, as both chemical and gene therapy SARM1 inhibitors
block axon loss (28–30).
The role of SARM1 in neurodegenerative disease has primarily been tested in the mouse. Although mouse models of CMT2A
exist, they have significant limitations (3). Overexpression of
human CMT2A–associated MFN2 variants using different transgenic systems leads to significant phenotypic heterogeneity (31–
35), whereas knockin (KI) of a pathogenic mutation into the endogenous mouse Mfn2 locus does not cause axonal defects (36). To
overcome these obstacles in this study, we analyzed the recently
described Mfn2-KI rat model (37) carrying the strong pathogenic human mutation H361Y (38). This model recapitulates many
aspects of human CMT2A (39). We analyzed the neuropathology
in this rat model and found a progressive motor axonopathy with
neuromuscular junction (NMJ) defects and muscle atrophy. In
addition, we observed numerous mitochondrial defects including fewer mitochondria at synapses, abnormal accumulation of
aggregated mitochondria near nodes of Ranvier, and mitochondrial shape and cristae density defects that were most prominent in
distal portions of the nerve. We generated the Sarm1-KO rat as well
as the Mfn2H361Y Sarm1 double-mutant rat in order to test the role of
SARM1 in CMT2A. We demonstrate that SARM1 was required for
axon degeneration, NMJ defects, muscle weakness, and hind limb
muscle atrophy in the Mfn2H361Y rat. Therefore, SARM1 was a key
driver of neuropathology in this model of CMT2A. Since mutant
MFN2 protein is present in the Mfn2H361Y Sarm1 rat, we expected
that mitochondrial defects would persist. Instead, SARM1 deletion
also suppressed defects in mitochondrial localization, size, number, and cristae density. In addition, we observed that deletion of
SARM1 improved mitochondrial axon transport in an in vitro assay.
These surprising findings demonstrate that dysfunctional mitochondria activated SARM1 to cause the major neuropathological
defects in this CMT2A model, and that activated SARM1 fed back
onto mitochondria, exacerbating their dysfunction. Hence, SARM1
inhibition is a compelling therapeutic candidate for the treatment
of CMT2A and, potentially, the many other neurodegenerative diseases characterized by mitochondrial dysfunction.

Results

Mfn2H361Y/+ rats recapitulate CMT2A neuromuscular phenotypes.
Patients with CMT2A have loss of vibratory sense as well as motor
weakness that is predominantly in the distal lower limbs and rapidly progresses throughout the first decade of life (1). Sural nerve
pathology demonstrates loss of large myelinated fibers with regenerating clusters, but no myelin abnormalities (5). Mitochondrial
abnormalities include swelling and dissolution of cristae, as well
as aggregation within the axon (4, 39–41). To model this disease,
the Mfn2H361Y mutation, which causes severe early-onset disease
in patients, was introduced into the rat genome using CRISPR/
Cas9. This model develops progressive functional abnormalities
and loss of myelinated axons (37). To investigate the neuronal
pathologies in Mfn2H361Y/+ rats, we examined the hind limb nerves
and muscles of Mfn2H361Y/+ rats at 6 and 12 months of age. Axons in
the sciatic nerve were intact at 6 months of age, but by 12 months,
we observed severe axon loss in the distal sciatic nerve (Figure
1A and Figure 2C). Morphometric analysis of axon diameters in
2

12-month-old Mfn2H361Y/+ rats revealed a decrease in large-caliber
axons that was mirrored by an increase in the proportion of small
fibers (Figure 1B). This axon size distribution is consistent with a
motor neuropathy (42) and is similar to that observed in CMT2A
human nerves (39). Patients with CMT2A have symptoms mainly
in the lower legs, attributed to more extensive distal axonal degeneration. Tellingly, we observed no axonal defects in proximal sciatic nerves in Mfn2H361Y/+ rats (Figure 1A), consistent with a lengthdependent neuropathy. Another pathological signature of CMT2A
peripheral nerves is the presence of clusters of regenerating axons
along with atrophied axons and onion bulb structures, cardinal evidence of repetitive axonal degeneration and regeneration (39). To
detect regenerating axons in distal hind limb nerves, we performed
immunostaining for STMN2, a marker of regenerating axons (43).
We detected many STMN2+ axons in 12-month-old Mfn2H361Y/+ tibial nerves, whereas only a few STMN2-labeled axons were seen in
the nerves of 6-month-old Mfn2H361Y/+ or WT rats (Figure 1C).
A number of motor-predominant neurodegenerative diseases involve abnormalities of the structure of the NMJ, an early
and important site of neuropathology in type 2 axonal CMT (44).
We stained NMJs in lumbrical muscles with antibodies against
neurofilament (axon marker) and SV2 (synapse vesicle marker)
and α-bungarotoxin (BTX) (postsynaptic marker). Morphological
abnormalities found in the NMJs of 12-month-old Mfn2H361Y/+ rats
included thin terminal axons and shrunken endplates (Figure 1D).
Of note, NMJs innervated by abnormally thin terminal axons have
been associated with models of motor neuron disorders including
ALS (45) and spinal and bulbar muscular atrophy (46). Lower leg
muscle atrophy is a typical clinical symptom of CMT2A (39), so
we searched for pathology in the hind paw lumbrical muscles of
12-month old Mfn2H361Y/+ rats. We found smaller muscle fascicles
(WT = 435.7 μm2 vs. Mfn2H361Y/+ = 356.2 μm2, n = 3, P = 0.045; Figure
1E) in the mutant rats, indicating that the Mfn2H361Y mutation causes progressive neuropathy in the hind limb. We also observed group
atrophy of muscle fibers that was characteristic of denervated muscle (Figure 1F). In chronic neurogenic muscle atrophy, denervated
muscle fibers are also reinnervated by neighboring motor axons,
which results in enlarged motor units with smaller muscle fibers as
well as a change in the distribution of muscle fiber types (i.e., fiber
type grouping) (47). Immunostaining with myosin heavy-chain
isoform–specific antibodies showed changes in the distribution of
muscle fiber types in gastrocnemius muscles of 12-month-old Mfn2H361Y rats (Figure 1G). The axonal degeneration, NMJ pathology,
and muscle atrophy in these Mfn2H361Y/+ rats suggested that they are
a faithful model of human CMT2A.
Sarm1 KO prevents Mfn2H361Y/+-associated axon and muscle
defects. SARM1 is an essential component of the programmed axon
destruction pathway. Activation of SARM1 triggers axonal degeneration, and the deletion of SARM1 protects axons from acute
injury–induced Wallerian degeneration and toxic and metabolic
peripheral neuropathy (10, 11, 14–16, 47). However, to our knowledge, whether SARM1 is involved in progressive neurodegenerative conditions like CMT2A is untested.
To investigate whether SARM1 contributes to axonal degeneration in CMT2A, we generated Sarm1-mutant rats using CRISPR
gene editing (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI161566DS1).
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Figure 1. The Mfn2H361Y mutation causes progressive neurodegeneration and muscle wasting. (A) Toluidine blue–stained cross sections of sciatic nerves
from WT and Mfn2H361Y/+ rats at 6 and 12 months of age. (B) Distribution of axonal diameters of distal sciatic nerves in WT and Mfn2H361Y/+ rats at 6 and
12 months of age (n = 3). *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. (C) STMN2
in tibial nerves of WT and Mfn2H361Y/+ rats at 6 and 12 months of age. Graph shows the percentage of the STMN2 immunopositive area per mm2 for each
genotype and age (n = 3–5). ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. Original magnification, ×100. (D) Representative
images of NMJs in WT and Mfn2H361Y/+ rats at 6 and 12 months of age, stained in green to detect the marker synaptic vesicle glycoprotein 2A (SV2A) and the
axon marker neurofilament medium chain (NEFM) and in red with the postsynaptic endplate marker bungarotoxin. The upper graph exhibits terminal axon
diameters and the lower graph exhibits endplate volumes in WT and Mfn2H361Y/+ rats at 6 and 12 months of age (n = 3–4). ****P < 0.001, by 1-way ANOVA
with Dunnett’s multiple-comparison test. Scale bar: 20 μm. (E) Cross sections of H&E-stained lumbrical muscles from WT and Mfn2H361Y/+ rats at 6 and 12
months of age. Scale bar: 50 μm. (F) Representative image of group atrophy (encircled by dotted line) in 12-month-old Mfn2H361Y/+ rat muscle stained with
H&E. Scale bar: 50 μm. (G) Cross sections of gastrocnemius muscle from 12-month-old WT and Mfn2H361Y/+ rats; tissues were immunostained for myosin
heavy chain (MHC) type IIA (SC-71) and BF-F3 MHC type IIB to highlight altered fiber type distribution in the mutant animals. Scale bar: 50 μm.

The deletion of Sarm1 and consequent loss of SARM1 protein were
confirmed by DNA sequencing and Western blotting of brain lysates.
Sarm1-KO rats were further subjected to a sciatic nerve transection
assay to test the axon-protective phenotype of this Sarm1 loss-offunction allele. Plastic sections of distal sciatic nerve from Sarm1-KO

and WT rats were analyzed 7 days after transection (Supplemental
Figure 1D) and showed robust protection of the transected axons, as
has been previously reported in Sarm1-KO mice (10, 11).
The Sarm1-KO rats were then crossed with Mfn2H361Y/+ rats to
test whether loss of SARM1 prevents the pathology observed in this
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Figure 2. Sarm1 deletion protects nerves from axonal degeneration in Mfn2H361Y/+ rats. (A) Relative NAD+ levels in tibial nerves of 12-month-old WT, Mfn2H361Y/+, and Sarm1–/–Mfn2H361Y/+ rats. Values were normalized to WT (n = 3–4). **P < 0.01, by 1-way ANOVA with Dunnett’s multiple-comparison test. (B) Toluidine blue–stained cross sections of distal sciatic nerve and tibial nerve from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats. Scale bar: 100 μm. (C) The number
of axons per mm2 in proximal sciatic nerve (SN), distal sciatic nerve, and tibial nerve from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats (n = 3–4). *P < 0.05,
**P < 0.01, and ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. (D) Immunostaining for STMN2 (green) and NF-M (2H3 antibody,
red) in tibial nerve from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats. Scale bar: 100 μm. Graph shows the percentage of STMN2-immunopositive area per
mm2 for each genotype (n = 5). ***P < 0.005, by 1-way ANOVA with Dunnett’s multiple-comparison test. (E) Distribution of axonal diameters of distal sciatic
nerve from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats (n = 3). There was no significant difference between WT and Sarm1–/– Mfn2H361Y/+ rats in 0–4, 6–8, and
8 μm axons. *P < 0.05 and **P < 0.01, by 1-way ANOVA with Dunnett’s multiple-comparison test.

CMT2A model. To investigate whether SARM1 is activated in the
nerves of Mfn2H361Y/+ rats, we first measured the levels of NAD+, the
SARM1 substrate (8). When SARM1 is activated, it cleaves NAD+,
and NAD+ levels decrease. Liquid chromatography tandem mass
spectrometry (LC-MS/MS) revealed a reduction of NAD expression
levels in Mfn2H361Y/+ rat tibial nerves, whereas the levels remained
equivalent to WT levels in the nerves of Sarm1–/– Mfn2H361Y/+ double-mutant rats, consistent with SARM1 activation (Figure 2A).
Crucially, the dramatic axonal loss and increased number of regenerating axons (marked by STMN2 staining) observed in Mfn2H361Y/+
nerves were completely abrogated in 12-month-old Sarm1–/– Mfn2H361Y/+ rats (Figure 2, B–D). The altered distribution of axonal diameters in Mfn2H361Y/+ rat nerves was also suppressed in Sarm1–/– Mfn2H361Y/+ rats (Figure 2E), indicating the preservation of large-caliber
axons with deletion of Sarm1.
Along with the axonal deficits, the distal muscles in Mfn2H361Y/+
rats showed severe atrophy (Figure 1, E–G). We further investigated
4

these muscle defects and tested whether Sarm1 deletion would also
improve the loss of muscle integrity caused by the Mfn2H361Y/+ mutation. Group atrophy and abnormal localization of nuclei, which
indicate a history of repeated muscle fiber atrophy and regeneration (46–49) (Figure 3A, arrowhead) in Mfn2H361Y/+ rats, was ameliorated in Sarm1–/– Mfn2H361Y/+ rats (Figure 3A). In addition, the
fiber type grouping seen in Mfn2H361Y/+ muscle was not observed
in Sarm1–/– Mfn2H361Y/+ muscle (Figure 3B). Other muscle pathologies associated with motor neuropathy (50) and denervated muscle fibers include changes in muscle fiber diameter (51). We used
laminin immunohistochemistry to highlight the muscle fibers and
analyzed their cross-sectional area (CSA). We found an increased
number of small-caliber muscle fibers (Figure 3C, arrows) and a
corresponding decrease in large-caliber muscle fibers in Mfn2H361Y/+
rats (Figure 3D). Muscle denervation is often associated with
increased fibrosis due to excessive accumulation of extracellular
matrix that replaces functional tissue (52). Picrosirius red staining

J Clin Invest. 2022;132(23):e161566 https://doi.org/10.1172/JCI161566
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Figure 3. Sarm1 deletion prevents muscle atrophy in Mfn2H361Y/+ rats. (A) Cross sections of H&E-stained tibial anterior muscle from WT, Mfn2H361Y/+, and
Sarm1–/– Mfn2H361Y/+ rats. Arrowheads indicate nuclei positioned in the center of myofibers, a feature of regenerated muscle. Scale bar: 50 μm. (B) Cross
sections of gastrocnemius muscle immunostained for MHC type IIA (SC-71 antibody) and IIB (BF-F3 antibody); muscle tissue was from WT, Mfn2H361Y/+, and
Sarm1–/– Mfn2H361Y/+ rats. Altered distribution of muscle fiber type was observed only in Mfn2H361Y/+ muscle. Scale bar: 50 μm. (C) Cross sections of lumbrical
muscle immunostained for laminin; muscle tissue was from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats. Arrows indicate small atrophied muscle fascicles.
Scale bar: 50 μm. (D) Distribution of cross-sectional area of tibial anterior muscle fascicles from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats (n = 3). *P <
0.05, by 1-way ANOVA with Dunnett’s multiple-comparison test. (E) Cross sections of Picrosirius red–stained tibial anterior and lumbrical muscle from WT,
Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats. Scale bar: 50 μm. (F) Hind limb grip strength measurements performed on 12- to 17-month-old WT, Mfn2H361Y/+, and
Sarm1–/– Mfn2H361Y/+ rats (n = 11–12). *P < 0.05, by 1-way ANOVA with Dunnett’s multiple-comparison test.

to detect collagen fibers showed increased collagen fiber content
in Mfn2H361Y/+ muscles, with more severe fibrosis and atrophy in
lumbrical muscles than in tibialis anterior (TA) muscles, suggesting that the denervation and associated muscle atrophy were more
severe at distal than at proximal nerve endings (Figure 3E). In contrast to these results, muscles from Sarm1–/– Mfn2H361Y/+ rats showed
no change in muscle fiber caliber or evidence of fibrosis (Figure
3, C–E). We next investigated whether the preservation of muscle
structure was accompanied by maintenance of muscle function.
We tested hind limb grip strength in WT, Mfn2H361Y/+, and Sarm1–/–
Mfn2H361Y/+ rats. The reduction of grip strength in Mfn2H361Y/+ rats was
recovered in Sarm1–/– Mfn2H361Y/+ rats (Figure 3F), demonstrating
that loss of SARM1 preserved muscle function. Together, these
results are consistent with distal-predominant nerve and muscle pathologies in this CMT2A model. Further, they indicate that
the axon degeneration and muscle atrophy due to mitochondrial

dysfunction caused by Mfn2 mutation required SARM1 activity,
demonstrating that SARM1 plays a crucial role in chronic, progressive neuropathy in addition to its known roles in acute injury.
Mfn2H361Y/+ NMJ abnormalities are dependent on SARM1 activity.
NMJ morphological abnormalities leading to loss of integrity vary
among motor neuron diseases and are correlated with symptom
severity (44, 53, 54). To examine the influence of Sarm1 deletion
on mutant Mfn2-derived alterations in NMJ morphology, we first
classified lumbrical muscle NMJs into the following 3 categories
defined previously by others (55, 56) (Figure 4A): (a) “normal
NMJs” with typical axonal diameters at terminals (>1.8 μm) and
synaptic terminal branches closely opposed to acetylcholine receptor–rich endplates; (b) “thin NMJs” with narrow axonal diameters
(<1.8 μm) and a mixture of retained (arrow) or eliminated (arrowhead) junctions; and (c) “denervated NMJs” with BTX-labeled
postsynaptic sites lacking presynaptic structures or terminal axons.

J Clin Invest. 2022;132(23):e161566 https://doi.org/10.1172/JCI161566
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Figure 4. Sarm1 deletion protects degenerating NMJs in Mfn2H361Y/+ rats. (A) Representative images of Mfn2H361Y/+ NMJs with various morphologies stained
to detect the synaptic vesicle marker SV2A (SV2), the axon marker NEFM (2H3), and the postsynaptic endplate marker BTX. The arrow indicates an endplate
innervated by a thin axon, and the arrowhead indicates an endplate which lacks a presynaptic structure. Scale bar: 20 μm. (B) Percentage of each NMJ category
in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ lumbrical muscles (n = 4). **P < 0.01, and ****P < 0.001, for WT versus Mfn2H361Y/+ or Sarm1–/– Mfn2H361Y/+; ##P < 0.01
and ###P < 0.005, for Mfn2H361Y/+ versus Sarm1–/– Mfn2H361Y/+; 1-way ANOVA with Dunnett’s multiple-comparison test (C) Representative images of NMJs in
WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ lumbrical muscles. Scale bar: 20 μm. (D) Number of NMJs per mm3 in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ lumbrical
muscles (n = 3–4). (E) Terminal axon diameters in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ lumbrical muscles (n = 3–4). *P < 0.05 and **P < 0.01, by 1-way
ANOVA with Dunnett’s multiple-comparison test. (F) Endplate volume in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ lumbrical muscle NMJs (n = 3–4). ****P <
0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. Some data in E and F are repeated from Figure 1D for comparison. (G) Electron microscopic
images of NMJs in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ lumbrical muscles. Scale bar: 500 nm. (H) Number of synaptic clefts per μm2 in WT, Mfn2H361Y/+, and
Sarm1–/– Mfn2H361Y/+ lumbrical muscle NMJs (n = 3–4). **P < 0.01 and ***P < 0.005, 1-way ANOVA with Dunnett’s multiple-comparison test.

Mfn2H361Y/+ rats had few normal NMJs (Mfn2H361Y/+ 20.8%; WT
71.6%), with most of their NMJs classified as thin (70.5%) and a
few as denervated (8.8%) (Figure 4, B and C).
Performing similar analyses of Sarm1–/– Mfn2H361Y/+ muscles, we
found that the endplates and terminal axons looked morphologically normal, with a significantly lower percentage of abnormal NMJs
6

compared with Mfn2H361Y/+ (thin NMJs, 46.1%; denervated NMJs,
6.3%) (Figure 4, B, C, and E). The number of NMJs in Mfn2H361Y/+
muscle was not altered (Figure 4D), however, there was a clear
reduction in endplate volume. This reduced endplate volume was
completely suppressed by SARM1 loss (Figure 4F), suggesting that
the degeneration of muscle fiber segments underlying the synapse

J Clin Invest. 2022;132(23):e161566 https://doi.org/10.1172/JCI161566
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was due to muscle fiber denervation (57). Furthermore, ultrastructural analysis of the NMJ revealed severe disorganization with loss
of synaptic clefts between pre- and postsynaptic membranes in Mfn2H361Y/+ rats and increased collagen fibers in the presynaptic space,
consistent with a loss of normal synaptic innervation. In contrast,
there were no ultrastructural abnormalities detected in Sarm1–/–
Mfn2H361Y/+ synapses (Figure 4, G and H). In summary, the Mfn2H361Y
mutation caused NMJ atrophy in a SARM1-dependent manner, suggesting that mitochondrial dysfunction largely led to NMJ and axonal damage via SARM1 activation.
Mitochondrial defects in Mfn2H361Y/+ distal nerves are mitigated
by SARM1 deficiency. MFN2 is localized in the mitochondrial outer membrane and is a key player in mitochondrial oxidative function, mitochondrial fusion and transport, ER-mitochondria tethering, and other mitochondrial functions (3). As such, mitochondrial
pathology is expected to be associated with MFN2 mutations, and,
indeed, the mitochondria in the nerves of patients with CMT2 display altered morphology and distribution (2). Mitochondria are also
actively recruited to synapses to support synaptic activity by maintaining local ATP synthesis (58). Therefore, to examine the effects
of Mfn2 mutation on synaptic mitochondria, we analyzed the number and morphology of mitochondria around the NMJs of lumbrical
muscles in Mfn2H361Y/+ rats by electron microscopy. We found a significant reduction in the number of mitochondria in axon termini
of Mfn2H361Y/+ rats (Figure 5E). Furthermore, most of the presynaptic
mitochondria that were present at these distal synapses displayed a
swollen, rounded shape with either a low cristae density or a complete lack of discernible cristae (Figure 5A). Despite the intrinsic
mitochondrial defects in these rats, the mitochondria in Sarm1–
/–
Mfn2H361Y/+ synapses were present in normal numbers and had
largely typical morphology. They were slightly swollen compared
with WT synapses (Figure 5, A–C), but cristae density was normal
(Figure 5D). We also examined mitochondria in the postsynaptic
muscle and observed no abnormalities in the Mfn2H361Y/+ animals
(Figure 5, F and G), consistent with observations in samples from
patients with CMT2 (2). That SARM1 loss suppressed mitochondrial abnormalities caused by a defective intrinsic mitochondrial protein, MFN2, was surprising and suggests a feedback loop between
mitochondrial dysfunction and SARM1 activation triggering a
cascade of increasing mitochondrial damage.
Electron microscopic analysis of Mfn2H361Y/+ sciatic and tibial
nerve axons also revealed abnormal mitochondria with the same
swollen, rounded shape reminiscent of human CMT2A pathology
(Figure 6A) (2). Here again, a striking distal preference was apparent in the Mfn2H361Y/+ rat, as the most severe mitochondrial morphological abnormalities were observed at synapses (Figure 5B),
followed by distal and then proximal nerve segments (Figure 6,
B–D). In contrast, mitochondria in Mfn2H361Y/+ neuronal cell bodies
appeared normal (Figure 6E). Thus, the preponderance of mitochondrial deficits occurred in the more distal regions of the nerve
including distal axons and, ultimately, at the synapse, consistent
with the more severe degeneration of these structures observed in
CMT2A neuropathy. The pathological mitochondrial abnormalities
were again mitigated by loss of Sarm1, with the mitochondrial cristae density in Sarm1–/– Mfn2H361Y/+ animals being largely normal (Figure 6D). However, the majority of Sarm1–/– Mfn2H361Y/+ mitochondria
still had an aberrantly rounded shape in distal nerves (Figure 6C).

Mitochondria play a central role in energy generation, metabolite synthesis, and calcium buffering (59). Thus, their proper localization in neurons is essential for normal function, and their sparsity in distal regions of the nerve and at the NMJ is likely involved
in the pathophysiology of CMT2A. The scarcity of mitochondria in
these regions led us to examine their distribution in axons from sciatic and tibial nerves. We found large, abnormal accumulations of
mitochondria around the juxtaparanode in Mfn2H361Y/+ axons (Figure
6F), particularly in the distal regions (Figure 6G). Almost all of the
mitochondria in these abnormal accumulations had an abnormally
rounded shape (Figure 6F). Consistent with the above results, the
loss of SARM1 decreased the numbers of mitochondria that accumulated in the juxtaparanodal regions of Sarm1–/– Mfn2H361Y/+ axons
(Figure 6F). The suppression of these mitochondrial abnormalities
by loss of SARM1 again suggests an interplay between mitochondrial health and SARM1 axonal energy regulation.
Mitochondrial transport defect in Mfn2H361Y/+ axons is prevented
by Sarm1 KO. MFN2 is necessary for mitochondrial transport in
cultured embryonic sensory neuron axons (60), and mitochondrial density was decreased at more distal sites in the Mfn2H361Y/+ rat,
suggesting that mitochondrial transport may be affected in these
animals. To investigate the effect of the Mfn2H361Y mutation on mitochondria motility, we infected cultured adult rat dorsal root ganglion (DRG) neurons with Mito-GFP lentivirus to visualize mitochondria in axons. Time-lapse imaging and kymograph analysis
demonstrated a significant decrease in mitochondrial motility in
Mfn2H361Y/+ axons (Figure 7, A–C), with a significant increase in the
percentage of stationary mitochondria and a decreased velocity of
the motile mitochondria (Figure 7, A and B). By contrast, the number
of stationary mitochondria and mitochondrial motility in Sarm1–/–
Mfn2H361Y/+ axons were similar to what was observed in WT neurons (Figure 7, B and C), indicating that SARM1 activity influences
axonal transport and/or the ability of mitochondria to engage the
transport machinery. Taken together, these results suggest that
SARM1 activity is primarily responsible for the mitochondrial motility defects in axons in the Mfn2H361Y mutant.

Discussion

CMT2A is a debilitating axonal neuropathy with prominent axon
loss and muscle wasting that is caused by mutations in the mitochondrial fusion protein MFN2. Here, we characterize a recently
described rat CMT2A model (37) and demonstrate that it displayed
both the hallmark neuropathological features and prominent mitochondrial abnormalities observed in the human disease. SARM1,
the central executioner of pathological axon degeneration, is an
inducible NAD+ hydrolase that can be activated by mitochondrial
dysfunction, and we therefore hypothesized that SARM1 mediates
the pathology in CMT2A. We generated Sarm1-KO rats as well as
Sarm1 Mfn2 double-mutant rats and found that deletion of Sarm1
rescued the axonal, synaptic, and muscle structure and function
defects in this CMT2A model. Hence, we believe that SARM1 inhibition is an exciting therapeutic candidate for CMT2A. Surprisingly, not only did Sarm1 KO rescue neuropathological phenotypes,
but it also suppressed many of the morphological characteristics
of mitochondria associated with mutation of MFN2. These findings identify a positive feedback loop whereby dysfunctional mitochondria activate SARM1, which in turn exacerbates mitochondrial
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Figure 5. Sarm1 deletion rescues mitochondrial defects in the synapses of Mfn2H361Y/+ rats. (A) Representative images of mitochondria in synapses of WT,
Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats. Scale bar: 1 μm. (B) Percentage of elongated (circularity = 0.7–1), oval (0.5–0.7), and rounded (0–0.5) mitochondria
in synapses (n = 3). *P < 0.05, ***P < 0.005, and ****P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. (C) Quantification of mitochondria size in synapses (n = 3). *P < 0.05 and ***P < 0.005, by 1-way ANOVA with Dunnett’s multiple-comparison test. (D) Quantification of cristae density
of mitochondria in synapses (n = 3). *P < 0.05 and **P < 0.01, by 1-way ANOVA with Dunnett’s multiple-comparison test. (E) Quantification of mitochondria density in synapses (n = 3). **P < 0.01 and ***P < 0.005, by 1-way ANOVA with Dunnett’s multiple-comparison test. (F) Representative images of
mitochondria in muscle from WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ rats. Scale bar: 1 μm. (G) Quantification of mitochondrial size in muscle (n = 3).

dysfunction. We believe this discovery has important implications
for the potential efficacy of SARM1 inhibition in the many neurodegenerative diseases with prominent mitochondrial dysfunction. SARM1 inhibition may not only block downstream axon loss,
but may also mitigate upstream mitochondrial pathology for which
no current treatments exist.
SARM1 is an essential driver of neuropathology in CMT2A.
CMT2A is a debilitating neuropathy that usually leaves patients
nonambulatory as children. It is the most common of the axonal
8

CMT neuropathies and is caused by mutations in the mitochondrial fusion protein MFN2. As such, the proximate molecular cause
is well understood: loss of MFN2 function disrupts mitochondrial
fusion as well as many mitochondrial functions including mitophagy, transport, and interorganelle communication. The fundamental
pathological defect in CMT2A is a distal-predominant, dying-back
motor and sensory axonopathy with marked muscle atrophy and
associated weakness. How do these mitochondrial defects result
in dying-back axon loss? Two prominent explanations are that
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Figure 6. Sarm1 deletion rescues mitochondrial defects in the axons of Mfn2H361Y/+ rats. (A) Electron microscope images of proximal sciatic and tibial
nerves from WT and Mfn2H361Y/+ rats showing representative axonal mitochondria. (B) Percentage of elongated, oval, and rounded mitochondria categorized
by their circularity in three different Mfn2H361Y/+ nerves (n = 3). **P < 0.01, comparison between proximal sciatic and tibial; 1-way ANOVA with Dunnett’s
multiple-comparison test. (C) Percentage of elongated, oval, and rounded mitochondria categorized by their circularity in WT, Mfn2H361Y/+, and Sarm1–/–
Mfn2H361Y/+ tibial nerve axons (n = 3–4). *P < 0.05, ***P < 0.005, and ****P < 0.001, comparison between WT and mutant; 1-way ANOVA with Dunnett’s
multiple-comparison test. Mfn2 H361Y/+ data is repeated from B for comparison. (D) Cristae density of mitochondria in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ tibial nerve axons (n = 3–4). **P < 0.01 and ***P < 0.001, by 1-way ANOVA with Dunnett’s multiple-comparison test. (E) Electron microscopic
images of mitochondria in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ motor neuron cell bodies (n = 3). Scale bar: 1 μm. Graph indicates mitochondrial size in
neuronal cell bodies (n = 3). (F) Representative electron microscopic images of longitudinal axons in tibial nerves showing nodes of Ranvier. Lower images
are magnified views of the frames in the upper images showing aggregated mitochondria. Graph represents the number of mitochondria per 10 μm2 of
paranode in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ axons (n = 3). *P < 0.05 and **P < 0.01, by 1-way ANOVA with Dunnett’s multiple-comparison test.
(G) Number of mitochondria per 10 μm2 area of paranode of the proximal sciatic nerve, distal sciatic nerve, and tibial nerve in Mfn2H361Y/+ rats (n = 3). *P <
0.05, by 1-way ANOVA with Dunnett’s multiple-comparison test..

dysfunctional mitochondria cannot meet the axon’s high energy
demands, and/or they fail to sufficiently buffer calcium (3, 59).
These are both reasonable possibilities, since loss of ATP and calcium influx are 2 important drivers of axon loss. According to these

explanations, the distal predominance of the pathology is attributed
to defects in mitochondrial transport. However, the identification of
SARM1 as the central executioner of axon degeneration in response
to pathological insults, including mitochondrial damage, raised an
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induces SARM1 activation (20). Prodegenerative stimuli that activate SARM1 include different types of mitochondrial poisons (24, 25), and
these toxins induce the loss of NMNAT2 (26, 27),
possibly due to defects in NMNAT2 transport.
However, while reduced NMNAT2 transport
to distal axons may be a straightforward explanation linking mitochondrial dysfunction and
SARM1 activation, we suggest a further, complementary mechanism. Since NMNAT2 requires
ATP to synthesize NAD+ from NMN, impaired
Figure 7. Sarm1 deletion rescues mitochondria motility in axons of Mfn2H361Y/+ rats. (A) Representative kymographs of mitochondrial movement in DRG axons. Scale bar: 10 μm. (B) Percentage of
mitochondrial oxidative phosphorylation that
stationary mitochondria in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ DRG axons (n = 3). **P < 0.01
impacts local ATP levels could also hinder NAD+
and ***P < 0.005, by 1-way ANOVA with Dunnett’s multiple-comparison test. (C) Motile mitosynthesis, thus promoting SARM1 activation
chondrial velocity in WT, Mfn2H361Y/+, and Sarm1–/– Mfn2H361Y/+ DRG axons (n = 3). *P < 0.05, by 1-way
even in the presence of NMNAT2. These proANOVA with Dunnett’s multiple-comparison test.
posed mechanisms are not specific to CMT2A
and MFN2 and suggest that SARM1 activation
is a common feature of many neurological disoralternate hypothesis — that dysfunctional mitochondria in CMT2A
ders with mitochondrial dysfunction. If so, SARM1 inhibition may
activate SARM1, and that SARM1 activity, rather than mitochonbe a broadly applicable therapeutic strategy.
dria-autonomous defects, triggers the progressive dying-back axoA mitochondrial-SARM1 feedback loop exacerbates mitochondrial
nopathy. Here, we provide strong support for this latter hypothesis.
dysfunction in CMT2A. Loss of SARM1 not only suppressed pathoOur analysis of pathology in the recently described Mfn2H361Y-KI
logical phenotypes in this CMT2A model, but also prevented many
rat model of CMT2A (37) demonstrated good concordance with
of the mitochondrial defects. This is an unexpected result, as pathothe human disease, i.e., progressive distal-predominant axonopagenic MFN2, a mitochondrial outer membrane protein, was still
thy with muscle atrophy and NMJ defects. Prominent staining for
present. If mitochondrial defects were due solely to the loss of MFN2
the axon regeneration marker stathmin 2 (STMN2) (43) also probiochemical function, then those defects should not be suppressed
vided strong evidence for compensatory axon regeneration in oldby loss of SARM1. Instead, our findings imply that activated SARM1
er nerves. To examine the contribution of SARM1 activity to these
feeds back onto mitochondria and exacerbates the mitochondrial
phenotypes, we used CRISPR-mediated gene editing to generate a
phenotypic abnormalities. This idea of a mitochondria-SARM1 feedSarm1-KO rat and then produced Mfn2H361Y Sarm1 double-mutant
back loop is consistent with the demonstration that SARM1 is actirats. The absence of SARM1 dramatically suppressed the pathovated by mitochondrial dysfunction (7, 24, 26, 27) and that SARM1
logical defects associated with Mfn2 mutation, rescuing the hallactivation causes mitochondrial dysfunction (ref. 9, and reviewed
mark axonal, synaptic, and muscle abnormalities. Hence, although
in ref. 62). However, the mechanism by which SARM1 acts upon
compromised mitochondrial function initiates disease, SARM1 is
mitochondria remains undetermined. It is instructive to consider
the ultimate driver of neuropathology. If these results hold true in
which phenotypes were and were not suppressed by loss of SARM1.
patients, then they have important therapeutic implications, as inhiIn Mfn2-mutant neurons, mitochondria take on a much more roundbition of SARM1 would be predicted to dramatically slow disease
ed shape than is seen in WT neurons, consistent with the known
progression. Both small-molecule and gene therapy SARM1 inhibiroles of mitochondrial fusion as a direct regulator of mitochondrial
tors block axon loss in vitro and in vivo (15, 28, 29), and adeno-assoshape (4). Although there was a modest trend toward improvement
ciated virus–mediated (AAV-mediated) delivery of a SARM1 domof this phenotype with loss of SARM1, the difference was not statisinant-negative transgene ameliorates behavioral and pathological
tically significant. In contrast, Sarm1 KO significantly suppressed
phenotypes in another model of a human motor neuropathy (21).
the decrease in mitochondrial cristae density observed in distal
How might MFN2 mutations lead to SARM1 activation? While
nerves and synapses of Mfn2-mutant animals. Cristae density is a
not yet fully understood, a strong hypothesis emerges from the
morphological defect that correlates with electron transport chain
mechanistic details of SARM1 activation (20). The potent SARM1
efficacy (63) and is therefore reflective of mitochondrial function.
antagonist and NAD+ synthetase NMNAT2 is a highly labile proSarm1 KO also fully suppresses the increase in the size of mitochontein whose levels are maintained through continuous transport
dria seen in the Mfn2 mutant. Mitochondrial swelling occurs when
from neuronal cell bodies to axons (61), such that NMNAT2 levels
ion homeostasis is impaired in the mitochondrial matrix, disrupting
are highly sensitive to disturbances in axon integrity, transport, or
osmotic balance and leading to water influx (63–65). Sarm1 KO also
energetics, especially in the most distal portions of long axons. In
rescues the large decrease in the number of synaptic mitochondria,
healthy axons, NMNAT2 suppresses SARM1 activation by locally
which may reflect improvements in both the morphological integrigenerating NAD+ from its precursor NMN. SARM1 is a metabolic
ty and axonal transport of mitochondria. For instance, the reduced
sensor regulated by the competitive binding of NAD+ and NMN to
mitochondrial mobility and velocity observed in axons of cultured
an allosteric binding site in its N-terminal autoinhibitory domain.
adult sensory neurons from Mfn2H361Y rats are rescued in Mfn2H361Y
+
An increase in the NMN/NAD ratio, as occurs when axonal
Sarm1 double-mutant neurons. Finally, an additional mitochondriNMNAT2 levels are low, leads to increased NMN occupancy and
al phenotype was present in the nerves of Mfn2-mutant rats — large
10
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accumulations of mitochondria in outpouchings adjacent to nodes
of Ranvier. While we do not know why mitochondria collected at this
location, it is a region of the axon with high energy requirements.
This phenotype was also partially suppressed by Sarm1 KO. Of
note, all of these mitochondrial defects became more prominent as
one moves distally down the nerve toward the synapse, consistent
with the preferential activation of SARM1 in distal axons where
short-lived NMNAT2 was first depleted. Taken together, these
findings suggest that, while mitochondrial morphology was surely
impacted by the direct loss of MFN2 function, all other mitochondrial phenotypes resulted primarily from the actions of SARM1.
How might activated SARM1 disrupt mitochondria? SARM1
is tethered to the outer mitochondrial membrane, and activated
SARM1 cleaves NAD+, which is essential for mitochondrial function. SARM1 cleaves cytosolic NAD+, and mitochondria have the
machinery to synthesize their own NAD+ via NMNAT3. However,
mitochondria also actively import NAD+ from the cytosol via the
transporter SLC25A51 (66, 67), suggesting that loss of cytosolic NAD+ could influence NAD+ mitochondrial pools and disrupt
NAD+-dependent mitochondrial activity including oxidative phosphorylation and ATP generation. In addition, SARM1 activity can
lead to rapid ATP loss via inhibition of glycolysis, which depends
on adequate NAD+ stores. Indeed, the ATP used for fast axonal
transport is preferentially generated by glycolysis (68), providing
another mechanism for SARM1-dependent mitochondrial transport defects and decreased numbers of synaptic mitochondria in
the Mfn2-mutant rat. Finally, SARM1 has been linked to mitophagy
proteins (69), suggesting it could regulate mitochondrial health in
other manners beyond the cleavage of NAD+.
The discovery of a mitochondrial dysfunction–SARM1 activation feedback loop has profound implications for understanding
the pathogenesis not only of CMT2A, but potentially other forms of
CMT2. Many CMT2 disease genes have been identified, and they
can be grouped into shared functions (70). Two of these shared
functions are mitochondrial homeostasis, as exemplified by mutations in MFN2 or OPA1, and defects in axonal transport, typified
by mutations leading to aberrant dynein and kinesin function. As
demonstrated here and in previous publications, mitochondrial defects can activate SARM1 (24–27), as can disruptions to axon
transport, because NMNAT2 transport is necessary to maintain
SARM1 autoinhibition. We suggest that a vicious cycle of mitochondrial dysfunction and SARM1 activation is initiated in CMT2
subtypes associated with disrupted mitochondrial activity or axonal
transport, ultimately resulting in SARM1-dependent axon loss and
CMT2 pathology. If correct, this hypothesis has 2 important implications. First, SARM1 inhibition may by a disease-modifying therapy for a broad class of CMT2 subtypes. Second, because mitochondrial dysfunction is a feature of many neurodegenerative disorders,
this destructive feedback loop may contribute to both the axonal
loss and mitochondrial dysfunction in these disparate diseases,
with both phenotypes amenable to SARM1-directed therapeutics.

Methods

Animals. As a model of CMT2A, rats which carry the p.His361Tyr Mfn2
mutation (referred to as Mfn2H361Y/+ rats) were generated using CRISPR/Cas9 gene editing technology (37). Functional testing of these
Mfn2H361Y/+ rats show abnormalities in gait dynamics at 8 weeks, with a

lengthening of the gait cycle by 16 weeks (37). To examine the contribution of SARM1 to CMT2A pathology, generated Sarm1-KO rats (referred
to here as Sarm1–/– rats) were generated using the SD1 strain. CRISPR/
Cas9 gene editing was used to generate rats with a 110 bp deletion in
Sarm1 exon 2 (Supplemental Figure 1A). This was performed by mixing
recombinant Cas9 protein with 2 guide RNAs (gRNAs) (Supplemental
Figure 1B) to produce ribonucleoprotein particles that were introduced
into rat embryos. To confirm Sarm1 KO, Western blotting was performed
using brain tissue. The SARM1 band was detected at 73 kDa in WT rats
and was not present in the Sarm1–/– rats (Supplemental Figure 1C).
NMJ staining and analysis. Rats were transcardially perfused with
20 mL 4% paraformaldehyde (PFA) solution. Dissected lumbrical
muscles were postfixed in 4% PFA overnight and then washed with
PBS for 15 minutes 3 times. Samples were permeabilized with 2% Triton X-100/PBS (PBST) for 30 minutes and then blocked with 4% BSA
in 0.3% PBST for 30 minutes at room temperature. Muscles were
incubated with anti-SV2 (Developmental Studies Hybridoma Bank,
AB2315387; 1:200) and anti-2H3 (Developmental Studies Hybridoma
Bank,; AB2314897;1:100) for 48 hours at 4°C. After incubation with primary antibodies, muscles were incubated with FITC rabbit anti–mouse
IgG (Invitrogen, Thermo Fisher Scientific, A21121; 1:400) overnight
at 4°C. The samples were then incubated with Alexa Fluor 568–conjugated BTX (Biotium, 00006; 1:500) for 2 hours at room temperature.
To analyze NMJ morphology, Z-stack images using a confocal microscope (Leica, DFC7000T) were obtained. Maximal intensity projection
images were reconstructed, and postsynapse volume and terminal axon
diameter were analyzed using Imaris software.
Immunohistochemistry. Fixed tissue was processed to make 15 μm
thick cryosections as described previously (71). Slides were washed with
PBS and blocked with 4% BSA dissolved in 0.3% PBST for 30 minutes
at room temperature. The slides were incubated with primary antibodies against STMN2 (43) (1:500), neurofilament-M (2H3; Developmental
Studies Hybridoma Bank AB2314897; 1:500), myosin heavy chain type
IIA (SC-71, Developmental Studies Hybridoma Bank, AB2147165; 1:500),
myosin heavy chain type IIB (BF-F3, Developmental Studies Hybridoma
Bank AB2266724; 1:500), or laminin (MilliporeSigma, L9393; 1:1,000)
overnight at 4°C. Slides were then washed and incubated with speciesappropriate secondary antibodies for 2 hours at room temperature.
Collagen staining with Picrosirius red. Paraffin sections (5 μm thick)
were prepared as described previously (71), and after deparaffinization, the sections were stained with a Picrosirius Red Kit (VitroVivo
Biotech) using the protocol provided. Sections were imaged using a
Nikon Eclipse 80i light microscope, and images were analyzed using
ImageJ software (NIH).
Mitochondria and NMJ ultrastructural analysis. Nerves and lumbrical muscles were processed, and plastic-embedded specimens were
prepared as described before (72). Sections (300–400 nm) were collected onto copper grids and then stained with uranyl acetate and lead
citrate and imaged by transmission electron microscopy (JEOL1200).
The detailed morphology of NMJs and mitochondria was analyzed
using ImageJ. Mitochondrial circularity was quantified using the following formula: circularity = 4π × area/perimeter2, as described in a previous report (73). As the value approaches 0.0, it indicates an increasingly
elongated polygon. A circularity value of 1.0 indicates a perfect circle.
Nerve structural analysis by light microscopy. For light microscope
analysis, plastic-embedded specimens were sectioned at 400–600
nm thickness using a Leica EM UC7 Ultramicrotome. Sections were
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stained with 1% toluidine blue solution. Axons were imaged using a
Zeiss Axioscope, and their diameter was analyzed using a IA32 Image
Analysis System. To examine the distribution of axonal diameters in
nerves, at least 100 axons were measured per rat.
Western blotting. Brain lysates were prepared as described before
(9). The following antibodies were used: rabbit anti-SARM1 (1:1,000;
13022, Cell Signaling Technology); mouse anti–β-actin (1:4,000; A222,
MilliporeSigma); HRP-conjugated anti-rabbit (1:5,000; AB 2307391,
Jackson ImmunoResearch); and HRP-conjugated anti-mouse (1:5,000;
115-035-003, Jackson ImmunoResearch).
Mass spectrometry. Tibial nerves were homogenized in 160 μL 50%
MeOH in water and then centrifuged (15,000g, 10 min). Chloroform
(50 μL) was added to the supernatant and centrifuged again (15,000g,
10 min). The clear aqueous phase was lyophilized, and metabolites
were measured as described previously (74).
DRG cultures. Ninety-six-well glass-bottomed tissue culture plates
(Cellvis, P96-0-N) were coated with poly-d-lysine (0.1 mg/mL; MilliporeSigma) and laminin (3 μg/mL; Invitrogen, Thermo Fisher Scientific) before DRG dissection. DRGs were dissected from adult rats
(10–12 months old) (L2–L5) and incubated with 0.5% collagenase
(Gibco, Thermo Fisher Scientific, 17104019) at 37°C for 1 hour. Cell
suspensions were then triturated by gentle pipetting and washed 3
times with DRG neurobasal growth medium (Gibco, Thermo Fisher Scientific, 21103049) containing 2% B27 (Invitrogen, Thermo
Fisher Scientific, 17504044), 100 ng/mL 2.5S NGF (Harlan Bioproducts), 1 μM 5-fluoro-2′-deoxyuridine (MilliporeSigma, 200-072-5),
penicillin, and streptomycin. Cell suspensions with densities of 2.0
× 105 cells/mL were prepared and 1.5 μL was placed in the center of
each well. Cells were allowed to adhere for 15 minutes, and then 100
μL DRG growth medium was added.
Mitochondrial motility analysis. DRG neurons were infected with
lentivirus expressing Mito-GFP (1 × 103 to 10 × 103 PFU) at 2 days in vitro
(2DIV). To analyze mitochondrial movement, Mito-GFP–labeled mitochondria in distal axons were monitored using the Zeiss Cell Discoverer

1. Bombelli F, et al. Charcot-Marie-Tooth
disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol.
2014;71(8):1036–1042.
2. Verhoeven K, et al. MFN2 mutation distribution
and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain. 2006;129(pt
8):2093–2102.
3. Dorn GW. Mitofusin 2 dysfunction and disease in
mice and men. Front Physiol. 2020;11:782.
4. Lv H, et al. A cohort study of Han Chinese
MFN2-related Charcot-Marie-Tooth 2A. J Neurol
Sci. 2015;358(1–2):153–157.
5. Vallat JM, et al. Histopathological findings in
hereditary motor and sensory neuropathy of axonal type with onset in early childhood associated
with mitofusin 2 mutations. J Neuropathol Exp
Neurol. 2008;67(11):1097–1102.
6. Figley MD, DiAntonio A. The SARM1 axon
degeneration pathway: control of the NAD+
metabolome regulates axon survival in health and
disease. Curr Opin Neurobiol. 2020;63:59–66.
7. Coleman MP, Höke A. Programmed axon degeneration: from mouse to mechanism to medicine.
Nat Rev Neurosci. 2020;21(4):183–196.

12

7 at 7DIV. Frames were collected every 15 seconds for 10 minutes.
Kymographs were generated using the Fiji image processing package in
ImageJ, and the percentage of motile mitochondria was quantified.
Statistics. GraphPad Prism (GraphPad Software) was used to perform statistical analyses by 1-way ANOVA with Dunnett’s multiple-comparison test. A P value of less than 0.05 was considered significant.
Study approval. All animal experiments were approved and performed under the direction of institutional animal study guidelines of
Washington University in St. Louis (protocol 20-0020).

Acknowledgments

We would like to thank members of the DiAntonio and Milbrandt
laboratories for their thoughtful feedback on this work. We thank
Cassidy Menendez, Rachel McClarney, and Alicia Neiner for their
technical support. We also thank members of the Washington University Core for Cellular Imaging (WUCCI) for their technical support, expertise, and training. We gratefully acknowledge the CMT
Association for providing the CMT2A-mutant rats. We also thank
the Genome Engineering and Stem Cell Center (GESC@MGI)
at Washington University for generating the Sarm1-KO rats. This
work was supported by NIH grants R01NS119812 (to AJB, AD, and
JM), R01NS087632 (to AD and JM), R37NS065053 (to AD), and
RF1AG013730 (to JM). This work was also supported by the Needleman Center for Neurometabolism and Axonal Therapeutics at the
Washington University Institute of Clinical and Translational Sciences, which is in part supported by the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) UL1 TR002345.
Address correspondence to: Jeffrey Milbrandt or Aaron DiAntonio, Department of Genetics, Washington University School of
Medicine, 4515 McKinley Ave, St. Louis, Missouri 63110, USA.
Phone: 1.314.362.2139; Email: jmilbrandt@wustl.edu (JM); Phone:
1.314.362.9925; Email: diantonio@wustl.edu (AD).

8. Essuman K, et al. The SARM1 Toll/interleukin-1
receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal
degeneration. Neuron. 2017;93(6):1334–1343.
9. Ko KW, et al. Live imaging reveals the cellular
events downstream of SARM1 activation. Elife.
2021;10:e71148.
10. Osterloh JM, et al. dSarm/Sarm1 is required for
activation of an injury-induced axon death pathway. Science. 2012;337(6093):481–484.
11. Gerdts J, et al. Sarm1-mediated axon degeneration
requires both SAM and TIR interactions. J Neurosci.
2013;33(33):13569–13580.
12. Henninger N, et al. Attenuated traumatic axonal
injury and improved functional outcome after
traumatic brain injury in mice lacking Sarm1.
Brain. 2016;139(pt 4):1094–1105.
13. Ko KW, et al. SARM1 acts downstream of
neuroinflammatory and necrotopic signaling to induce axon degeneration. J Cell Biol.
2020;219(8):e201912047.
14. Geisler S, et al. Prevention of vincristine-induced
peripheral neuropathy by genetic deletion of
SARM1 in mice. Brain. 2016;139(pt 12):3092–3108.
15. Geisler S, et al. Vincristine and bortezomib

use distinct upstream mechanism to activate a
common SARM1-dependent axon degeneration
program. JCI Insight. 2019;4(17):e129920.
16. Turkiew E, et al. Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy. J Peripher Nerv Syst. 2017;22(3):162–171.
17. Liu K, et al. Metabolic stress drives sympathetic neuropathy within the liver. Cell Metab.
2021;33(3):666–675.
18. Li Y, et al. Sarm1 activation produces cADPR
to increase intra-axonal Ca++ and promote axon degeneration in PIPN. J Cell Biol.
2022;221(2):e202106080.
19. Gilley J, Coleman MP. Endogenous Nmnat2 is
an essential survival factor for maintenance of
healthy axons. PLoS Biol. 2010;8(1):e1000300.
20. Figley MD, et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger
axon degeneration. Neuron. 2021;109(7):1118–1136.
21. Dingwell CB, et al. Macrophage depletion blocks
congenital SARM1-dependent neuropathy. J Clin
Invest. 2022;132(23):e159800.
22. Gilley J, et al. Enrichment of SARM1 alleles
encoding variants with constitutively hyperactive
NADase in patients with ALS and other motor

J Clin Invest. 2022;132(23):e161566 https://doi.org/10.1172/JCI161566

RESEARCH ARTICLE

The Journal of Clinical Investigation  
nerve disorders. Elife. 2021;10:e70905.
23. Bloom AJ, et al. Constitutively active SARM1 variants that induce neuropathy are enriched in ALS
patients. Mol Neurodegener. 2022;17(1):1.
24. Summers DW, et al. Mitochondrial dysfunction
induces Sarm1-dependent cell death in sensory
neurons. J Neurosci. 2014;34(28):9338–9350.
25. Sasaki Y, et al. cADPR is a gene dosage-sensitive
biomarker of SARM1 activity in healthy, compromised, and degenerating axons. Exp Neurol.
2020;329:113252.
26. Summers DW, et al. DLK activation synergizes
with mitochondrial dysfunction to downregulate
axon survival factors and promote SARM1-dependent axon degeneration. Mol Neurobiol.
2020;57(2):1146–1158.
27. Loreto A, et al. Mitochondrial impairment activates the Wallerian pathway through depletion
of NMNAT2 leading to SARM1-dependent axon
degeneration. Neurobiol Dis. 2020;134:104678.
28. Hughes RO, et al. Small molecule SARM1 inhibitors recapitulate the SARM1–/- phenotype and
allow recovery of a metastable pool of axons
fated to degenerate. Cell Rep. 2021;34(1):108588.
29. Bosanac T, et al. Pharmacological SARM1 inhibition protects axon structure and function in
paclitaxel-induced peripheral neuropathy. Brain.
2021;144(10):3226–3238.
30. Geisler S, et al. Gene therapy targeting SARM1
blocks pathological axon degeneration in mice. J Exp
Med. 2019;216(2):294–303.
31. Detmer SA, et al. Hindlimb gait defects due to
motor axon loss and reduced distal muscles in a
transgenic mouse model of Charcot-Marie-Tooth
type 2A. Hum Mol Genet. 2008;17(3):367–375.
32. Cartoni R, et al. Expression of mitofusin 2(R94Q)
in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain. 2010;133(pt
5):1460–1469.
33. Bannerman P, et al. Mice hemizygous for a pathogenic mitofusin-2 allele exhibit hind limb/foot gait
deficits and phenotypic perturbations in nerve and
muscle. PLoS One. 2016;11(12):e0167573.
34. Rocha AG, et al. MFN2 agonists reverse mitochondrial defects in preclinical models of
Charcot-Marie-Tooth disease type 2A. Science.
2018;360(6386):336–341.
35. Zhou Y, et al. Restoring mitofusin balance
prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model. J Clin Invest.
2019;129(4):1756–1771.
36. Strickland AV, et al. Characterization of the
mitofusin 2 R94W mutation in a knock-in mouse
model. J Peripher Nerv Syst. 2014;19(2):152–164.
37. Scheideler MA, et al. Charcot-Marie-Tooth Association, assignee. Rat models for CMT2A that
develop a progressive neuropathy 2019; U.S. Patent No. US 2020/0053991 A1. October 30, 2017.
38. Zuchner S, et al. Axonal neuropathy with optic
atrophy is caused by mutations in mitofusin 2.

Ann Neurol. 2006;59(2):276–281.
39. Chung KW, et al. Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain. 2006;129(pt
8):2103–2118.
40. Stuppia G, et al. MFN2-related neuropathies: clinical features, molecular pathogenesis and therapeutic perspectives. J Neurol Sci. 2015;356(1–2):7–18.
41. Lv H, et al. Mitofusin 2 gene mutation causing
early-onset CMT2A with different progressive
courses. Clin Neuropathol. 2013;32(01):16–23.
42. Taylor BV, et al. Multifocal motor neuropathy:
pathologic alterations at the site of conduction block.
J Neuropathol Exp Neurol. 2004;63(2):129–137.
43. Shin JE, et al. Dynamic regulation of SCG10 in regenerating axons after injury. Exp Neurol. 2014;252:1–11.
44. Spaulding EL, et al. Synaptic deficits at neuromuscular junctions in two mouse models
of charcot-marie-tooth type 2d. J Neurosci.
2016;36(11):3254–3267.
45. Bruneteau G, et al. Muscle histone deacetylase
4 upregulation in amyotrophic lateral sclerosis:
potential role in reinnervation ability and disease
progression. Brain. 2013;136(8):2359–2368.
46. Poort JE, et al. Neuromuscular junctions are
pathological but not denervated in two mouse
models of spinal bulbar muscular atrophy. Hum
Mol Genet. 2016;25(17):3768–3783.
47. Cheng Y, et al. Sarm1 Gene deficiency attenuates
diabetic peripheral neuropathy in mice. Diabetes.
2019;68(11):2120–2130.
48. Bongers KS, et al. Skeletal muscle denervation
causes skeletal muscle atrophy through a pathway
that involves both Gadd45a and HDAC4. Am J
Physiol Endocrinol Metab. 2013;305(7):E907–E915.
49. Folker ES, Baylies MK. Nuclear positioning in muscle
development and disease. Front Physiol. 2013;4:363.
50. Kim JK, et al. Muscle-specific SMN reduction
reveals motor neuron-independent disease in
spinal muscular atrophy models. J Clin Invest.
2020;130(3):1271–1287.
51. Daou N, et al. Displaced myonuclei in cancer
cachexia suggest altered innervation. Int J Mol
Sci. 2020;21(3):1092.
52. Rebolledo DL, et al. Denervation-induced skeletal
muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β. Matrix Biol. 2019;82:20–37.
53. Cipriani S, et al. Neuromuscular junction changes
in a mouse model of charcot-marie-tooth disease
type 4C. Int J Mol Sci. 2018;19(12):4072.
54. Court FA, et al. Remodeling of motor nerve terminals in demyelinating axons of periaxin-null
mice. Glia. 2008;56(4):471–479.
55. Schaefer AM, et al. A compensatory subpopulation of motor neurons in a mouse model of
amyotrophic lateral sclerosis. J Comp Neurol.
2005;490(3):209–219.
56. Ang ET, et al. Motor axonal sprouting and neuromuscular junction loss in an animal model of
Charcot-Marie-Tooth disease. J Neuropathol Exp

Neurol. 2010;69(3):281–293.
57. Rudolf R, et al. Degeneration of neuromuscular
junction in age and dystrophy. Front Aging Neurosci. 2014;6:99.
58. Devine MJ, et al. Mitochondria at the neurinal
presynapse in health and disease. Nat Rev Nerurosci. 2018;19(2):63–80.
59. Mandal A, Drerup CM. Axonal transport and
mitochondrial function in neurons. Front Cell
Neurosci. 2019;13:373.
60. Misko A, et al. Mitofusin 2 is necessary for
transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci.
2010;30(12):4232–4240.
61. Milde S, et al. Deletions within its subcellular
targeting domain enhance the axon protective
capacity of Nmnat2 in vivo. Sci Rep. 2013;3:2567.
62. Merlini E, et al. Mitochondrial dysfunction as
trigger of programmed axon death. Trends Neurosci. 2022;45(1):53–63.
63. Nielsen J, et al. Plasticity in mitochondrial
cristae density allows metabolic capacity modulation in human skeletal muscle. J Physiol.
2017;595(9):2839–2847.
64. Kaasik A, et al. Regulation of mitochondrial matrix volume. Am J Physiol Cell Physiol.
2007;292(1):C157–C163.
65. Javadov S, et al. Different approaches to modeling
analysis of mitochondrial swelling. Mitochondrion. 2018;38:58–70.
66. Luongo TS, et al. SLC25A51 is a mammalian
mitochondrial NAD+ transporter. Nature.
2020;588(7836):174–179.
67. Kory N, et al. MCART1/SLC25A51 is required
for mitochondrial NAD transport. Sci Adv.
2020;6(43):eabe5310.
68. Zala D, et al. Vesicular glycolysis provides
on-board energy for fast axonal transport. Cell.
2013;152(3):479–491.
69. Murata H, et al. SARM1 and TRAF6 bind to and
stabilize PINK1 on depolarized mitochondria.
Mol Biol Cell. 2013;24(18):2772–2784.
70. McCray BA, Scherer SS. Axonal Charcot-Marie-Tooth disease: from common pathogenic
mechanisms to emerging treatment opportunities. Neurotherapeutics. 2021;18(4):2269–2285.
71. Sasaki Y, et al. Dysregulation of NAD+ metabolism induces a schwann cell dedifferentiation
program. J Neurosci. 2018;38(29):6546–6562.
72. Sasaki Y, et al. SARM1 depletion rescues
NMNAT1-dependent photoreceptor cell death
and retinal degeneration. Elife. 2020;9:e62027.
73. Abbade J, et al. Increased placental mitochondrial fusion in gestational diabetes mellitus: an
adaptive mechanism to optimize feto-placental
metabolic homeostasis? BMJ Open Diabetes Res
Care. 2020;8(1):e000923.
74. Sasaki Y, et al. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD+
depletion. Elife. 2016;5:e19749.

J Clin Invest. 2022;132(23):e161566 https://doi.org/10.1172/JCI161566

13

